



"Tote Board, Hollywood Park, Century, Inglewood, CA, US" by jondoe407y1
<http://www.flickr.com/photos/jondoe407y1/2602455841/>
 Licensed under CC BY 2.0 via Commons

What shall we learn today?

Many analyses and concepts that relates to count data (tables), in particular odds.

An overly optimistic description: Lectures 3-5 but for categorical, rather than numerical, data.

For tables relating counts of a categorical variable, how can we test the distribution of values against

- a model (probability function), or
- between subgroups.

We will start with the special case of dichotomous/binary data (event or non-event).

Introduction to Biostatistics Lecture 6

Henrik Renlund



A note on categorical data

We generally talk differently about categorical data depending on the number of unique values.

Dichotomous/binary data is typically yes/no- or event/non-event data. We talk about this data in terms of the probability of one of the events (often the one with the smallest probability). If $\text{Prob}(\text{event})$ is modelled, then $\text{Prob}(\text{non-event})$ is implicit (since $\text{Prob}(\text{non-event}) = 1 - \text{Prob}(\text{event})$).

"Non-binary" categorical data has more than 2 values (A, B, C, \dots). We talk about this data in terms of the entire *distribution*, i.e. the probability function ($\text{Prob}(A), \text{Prob}(B), \text{Prob}(C), \dots$). Of course we could omit one of these, since it would be implicit, but it is inconvenient.

1 sample:

Suppose x_1, x_2, \dots, x_n is a sample from some population.

Numeric: population mean $= \mu$? Answered by 1-sample t -test (parametric) or Wilcoxon signed rank test (non-parametric).

Categorical: is the probability function $= p(k)$? Or, if binary, is $\text{Prob}(\text{event}) = p$? Answered by e.g. confidence interval for p or $\chi^2 - \text{test}$.

2-sample paired:

Numeric: taking differences reduces this to the 1-sample situation.

Categorical: McNemars test.

2 samples:

Suppose x_1, x_2, \dots, x_n and y_1, y_2, \dots, y_n are samples from possibly different populations.

Numeric: Are the population means the same? Answered by 2-sample t -test (parametric) or Mann-Whitney (non-parametric).

Categorical: are the probability function the same? Or, if binary, is $\text{Prob}(\text{event})$ the same? Answered by Fishers exact test or χ^2 -test.

Many samples:

Numeric: Are all means the same? Answered by ANOVA (parametric) or Kruskal-Wallis (non-parametric)

Categorical: Are all probability functions the same? Answered by χ^2 -test.

Dagbigatran is an anticoagulant used for e.g. stroke prevention in patients with atrial fibrillation. *The following example only looks at side effects.*

718 people were randomized to Dabigatran or placebo and observed for some set time for bleeding.

| id | intervention | bleeding |
|-----|--------------|----------|
| 1 | dabigatran | Yes |
| 2 | placebo | No |
| 3 | placebo | No |
| 4 | dabigatran | No |
| ⋮ | ⋮ | ⋮ |
| 718 | placebo | No |

| | Bleeding | | Sum |
|------------|----------|-----|-----|
| | Yes | No | |
| dabigatran | 27 | 320 | 347 |
| placebo | 8 | 363 | 371 |
| Sum | 35 | 683 | 718 |

Measures for dabigatran:

- Risk** (probability of an unwanted event)
Risk of bleeding $= 27/347 = 0.078$
- Odds** (how much more likely it is, versus not, to experience an event)
Odds of bleeding

$$= \frac{27/347}{320/347} = \frac{27}{320} = 0.084$$

(Odds? Sometimes this is easier to model.)

Odds ratio (OR)

Probabilities cannot be retrieved from the OR alone.

N.B.

- Odds = 1 means $p = 0.5$ (as likely to experience the event as to not experience the event)
- OR = 1 means events are equally likely in both groups

If you know the 'denominator' probability (p_2) then the 'numerator' probability (p_1) can be calculated

$$p_1 = \frac{OR \cdot p_2}{1 + (OR - 1) \cdot p_2}.$$


For small values of p_2 and 'moderate' values of OR

$$p_1 \approx OR \cdot p_2,$$

i.e.

$$OR \approx \frac{p_1}{p_2} = RR.$$

Simulate (500 times) the experiment of randomly selecting 35 people from the study population and record the number who got dabigatran (15, 15, 16, 18, 16...)



However, we can calculate *exactly* what the distribution of X is *given* H_0 (in this case).

The p -value is the probability of a discrepancy the size of that between the observed and the expected.

Fishers exact test

| | Bleeding | | Sum |
|------------|----------|-------------|-----|
| | Yes | No | |
| dabigatran | X | (347-X) | 347 |
| placebo | (35-X) | (683-347+X) | 371 |
| Sum | 35 | (683) | 718 |


Suppose that whether a person bleeds or not is independent of intervention. (H_0 : "odds ratio = 1".)

Then the 35 individuals who bled should be a random sample of the study population (of size 718) and we would expect that $X/35 = 347/718 \approx 48\%$.

We would expect X to be around 17, but is $X = 27$ within some acceptable range of possibilities?

p-value in Fishers exact test

Sum the yellow values to get $p = 0.00045$.



More on Fishers exact test

My software produced the following output:

Fisher's Exact Test for Count Data

```
data: Dabigatran_example
p-value = 0.0004458
alternative hypothesis: true odds ratio is not equal to 1
95 percent confidence interval:
 1.659358 9.877595
sample estimates:
odds ratio
 3.821942
```

So odds ratio is between 1.7 and 9.9. (Allows for hypothesis testing.)
 Probabilities are small, so risk of dabigatran is (approx.) between 1.7 and 9.9 times larger than placebo risk.

Absolute risk

What can we say about the *absolute* risk of bleeding with dabigatran?

This was covered by Lars in Lecture 3! (Genotype example.)

The risk estimate $27/347 = 0.078$ has a standard error (SE) given by

$$\sqrt{\frac{0.078(1 - 0.078)}{347}} = 0.0144.$$

This yields a 95% confidence interval given by

$$(0.078 \pm 1.96 \cdot 0.0144) = (0.050, 0.11).$$

(This allows for hypothesis testing.)

Rule of thumb: $n * \min(p, 1 - p) \geq 5$.

Risk difference

What is the *difference* in risk between dabigatran and placebo?

This has (almost) been covered by Lars. One needs to know that for two **independent** estimators (having SE_1 and SE_2) the SE for their difference is given by

$$\sqrt{SE_1^2 + SE_2^2}.$$

| Risk | Estimate | Standard error |
|------------|------------------------|---------------------------------------|
| dabigatran | $p_1 = 27/347 = 0.078$ | $\sqrt{p_1(1 - p_1)/347} = 0.0144$ |
| placebo | $p_2 = 8/371 = 0.022$ | $\sqrt{p_2(1 - p_2)/371} = 0.0075$ |
| difference | $p_1 - p_2 = 0.056$ | $\sqrt{0.0144^2 + 0.0075^2} = 0.0162$ |

We get a 95% confidence interval for the difference with

$$(0.056 \pm 1.96 \cdot 0.0162) = (0.024, 0.088).$$

(This allows for hypothesis testing.)

Have we exhausted the Dabigatran example yet?

It certainly seems so (but it will actually return again later in the lecture!)

Summary of the dabigatran example:

| Quantity | Estimate | Confidence interval |
|------------------------|----------|---------------------|
| p_1 | 0.078 | (0.050, 0.11) |
| $p_1 - p_2$ | 0.056 | (0.024, 0.088) |
| OR (p_1 vs. p_2) | 3.82 | (1.7, 9.9) |

Cosmetic skin testing

To prove a new product is hypoallergenic it should provoke no more skin reactions than current market leader.

To test a new product 40 individuals got both products applied to patches of skin and observed for reaction (yes/no)

| id | new | market |
|----|-----|--------|
| 1 | no | no |
| 2 | yes | no |
| 3 | no | no |
| ⋮ | ⋮ | ⋮ |
| 40 | yes | yes |

Is the new product as good as the market leader?

The following table is *not* appropriate to answer that question.

| | no | yes |
|-----|----|-----|
| old | 22 | 18 |
| new | 32 | 8 |

The rows are dependent.

Note:

One *can* estimate (and get confidence intervals) for p_1 and p_2 (risk of skin reaction with new and old, respectively).

But it is harder to quantify the SE for risk difference and OR, due to the dependence.

McNemars test for paired data

| | | new | | |
|----------|-----|-----|-----|----------|
| | | no | yes | Σ |
| market | no | 17 | 5 | 22 |
| | yes | 15 | 3 | 18 |
| Σ | | 32 | 8 | 40 |

McNemars test only considers the pairs where the results are different.

With new product there are 8 reactions but 3 of them would have happened anyway. The new product 'creates' 5 reactions, whereas the market leader 'creates' 15 reactions.

Switching from the market leader to the new product would benefit 15, make it worse for 5, and have no effect on 20. (In terms of skin reactions.)

A test statistic can be calculated. p -value for H_0 : 'no difference' is approx 4%.

Other situations

Twins being randomized to intervention or placebo:

| | | Placebo | |
|--------------|-------------|-------------|-----|
| | | improvement | non |
| Intervention | improvement | a | b |
| | non | c | d |

Before/after data:

| | | Before | |
|-------|-------|--------|-----|
| | | event | non |
| After | event | a | b |
| | non | c | d |

Mendel's pea experiment

One of Mendel's pea-experiments was a (dihybrid) cross between the genes for round/wrinkled seeds and yellow/green seeds.

| Type | RY | RG | WY | WG | Sum |
|---------------|-----|-----|-----|----|-----|
| Count (O) | 315 | 108 | 101 | 32 | 558 |

According to his theory, these should appear in ratios of 9:3:3:1. So, we have a model for X = "the type":

| Value v | RY | RG | WY | WG |
|-----------------|------|------|------|------|
| Prob($X = v$) | 9/16 | 3/16 | 3/16 | 1/16 |

χ^2 -tests

χ^2 tests are applied to tabulated data (i.e. the 'counts'), typically categorical data. (E.g. the Dabigatran data.)

Like the t -test, we can use χ^2 to compare a sample against a model or, compare 2 or more samples against each other.

χ^2 tests typically calculate a test statistic Q according to the formula

$$Q = \sum \frac{(\text{observed} - \text{expected})^2}{\text{expected}}.$$

Q is compared to a χ^2 distribution with a parameter (degrees of freedom) that depends on the situation.

This is not an exact test. Rule of thumb: expected cell count ≥ 5 .

Comparing data to a model


χ^2 -analysis:

| Type | RY | RG | WY | WG | Sum |
|---------------------------------|-------|-------|-------|-------|-------|
| Data (O) | 315 | 108 | 101 | 32 | 558 |
| H_0 model (p) | 9/16 | 3/16 | 3/16 | 1/16 | 1 |
| Expected ($E = 558 \times p$) | 313.9 | 104.6 | 104.6 | 34.9 | 558 |
| Q , i.e. $(O - E)^2/E$ | 0.004 | 0.111 | 0.124 | 0.241 | 0.479 |

If H_0 is correct then Q should be (approximately) $\chi^2(3)$. (3 = the number of categories -1 .)

Mendels hypothesis seems ok

The observed test statistic 0.47 is compatible with H_0 .



Comparing distributions


A case control study of coronary heart disease and drinking (none, moderate, heavy). Cases were matched on age, gender and smoking habits.

| | non | moderate | heavy | sum |
|----------|-----|----------|-------|-----|
| cases | 34 | 80 | 18 | 132 |
| controls | 156 | 334 | 38 | 528 |
| sum | 190 | 414 | 56 | 660 |

Does drinking habits differ between cases and controls?
If they do not (H_0), their distributions should be close to

| non | moderate | heavy |
|-----------------|-----------------|----------------|
| 28.8% (190/660) | 62.7% (414/660) | 8.48% (56/660) |

Visualizing the distributions



Are drinking categories equidistributed for cases and controls?

| | non | moderate | heavy | Sum |
|--|-------|----------|-------|-------|
| observed cases | 34 | 80 | 18 | 132 |
| observed controls | 156 | 334 | 38 | 528 |
| sum | 190 | 414 | 56 | 660 |
| prop. (p=sum/660) | 0.29 | 0.63 | 0.08 | (1) |
| expected cases (132·p) | 38.1 | 82.9 | 11.0 | (132) |
| expected controls (528·p) | 152.0 | 331.0 | 44.0 | (527) |
| Q cases ((Obs.-Exp.) ² /Exp.) | 0.43 | 0.10 | 4.4 | Tot: |
| Q controls | 0.11 | 0.026 | 1.1 | 6.2 |

The test statistic $Q = 6.2$ should be compared to a χ^2 with $(rows-1) \times (columns-1) = 1 \times 2 = 2$ degrees of freedom.
 $p = \text{Prob}(Q > 6.2) = 0.045$.

So the difference between cases and controls is statistically significant.

The large sample size gives this test a lot of power (ability to find differences).

Do not forget to look at the estimates!

| | non | moderate | heavy |
|---------------------|------|----------|-------|
| proportion cases | 0.26 | 0.61 | 0.13 |
| proportion controls | 0.30 | 0.63 | 0.07 |
| proportion total | 0.29 | 0.63 | 0.08 |

Whether these differences are significant in any other sense is for the researcher to discuss.

The χ^2 test can also be applied to our dabigatran data.

It tests if the distribution of complications (bleeding/not) is the same for the two groups.

Output from my software:

```
# Pearson's Chi-squared test with Yates'
# continuity correction
#
# data:  bord
# X-squared = 11.05, df = 1, p-value = 0.0008869
```

(Recall that Fisher’s exact test gave $p = 0.0004458$.)

Comparison of open surgery (OS) and percutaneous nephrolithotomy (PN) for removal of kidney stones.

(Data illustrates Simpson’s paradox.)

| | Total | | Adjusted for size | | | |
|----------------------|-------|-----|-------------------|-----|--------------|-----|
| | OS | PN | Small stones | | Large stones | |
| Success | 273 | 289 | 81 | 234 | 192 | 55 |
| Failure | 77 | 61 | 6 | 36 | 71 | 25 |
| Odds (for success) | 3.5 | 4.7 | 13.5 | 6.5 | 2.7 | 2.2 |
| Odds ratio (OS / PN) | 0.75 | | 2.1 | | 1.2 | |
| (Percent success) | 78% | 83% | 93% | 87% | 73% | 69% |

Here it seems like we should adjust for stone size.

(The **Mantel-Haenszel** test is a way to analyse several contingency tables.)

In observational studies we typically gather more information. E.g.

| Ind. | Bleeding | DE Dose | Age | Gender | Weight | ... |
|------|----------|---------|-----|--------|--------|-----|
| 1 | Yes | 50 | 75 | M | 83 | ... |
| 2 | No | 75 | 64 | F | 77 | ... |
| ⋮ | ⋮ | ⋮ | ⋮ | ⋮ | ⋮ | ⋮ |

When medicine is **not** randomized a simple cross tabulation analysis of 'Bleeding' versus 'DE Dose' is at risk of confounding.

One way to deal with this is logistic regression (more on that in a later lecture).